Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Elelyso Taliglucerase alfa Gaucher disease Do not list Complete
Eliquis Apixaban Venous thromboembolic events, treatment and prevention of recurrence List with clinical criteria and/or conditions Complete
Eliquis Apixaban Venous thromboembolic events, prevention List with clinical criteria and/or conditions Complete
Eliquis Apixaban Thromboembolic events prevention, (atrial fibrillation) List with clinical criteria and/or conditions Complete
Elrexfio elranatamab Relapsed or refractory multiple myeloma Reimburse with clinical criteria and/or conditions Active
Emend Aprepitant Nausea and Vomiting, Chemotherapy induced List with clinical criteria and/or conditions Complete
Emgality galcanezumab Episodic cluster headache Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Emgality galcanezumab Prevention of migraine Reimburse with clinical criteria and/or conditions Complete
Empaveli pegcetacoplan Paroxysmal nocturnal hemoglobinuria Reimburse with clinical criteria and/or conditions Complete
Enablex Darifenacin hydrobromide Bladder, overactive Do not list Complete